Literature DB >> 9531613

Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization.

J C Cigudosa1, P H Rao, M J Calasanz, M D Odero, J Michaeli, S C Jhanwar, R S Chaganti.   

Abstract

Clonal chromosomal changes in multiple myeloma (MM) and related disorders are not well defined, mainly due to the low in vivo and in vitro mitotic index of plasma cells. This difficulty can be overcome by using comparative genomic hybridization (CGH), a DNA-based technique that gives information about chromosomal copy number changes in tumors. We have performed CGH on 25 cases of MM, 4 cases of monoclonal gammopathy of uncertain significance, and 1 case of Waldenstrom's macroglobulinemia. G-banding analysis of the same group of patients demonstrated clonal chromosomal changes in only 13 (43%), whereas by CGH, the number of cases with clonal chromosomal gains and losses increased to 21 (70%). The most common recurrent changes detected by CGH were gain of chromosome 19 or 19p and complete or partial deletions of chromosome 13. +19, an anomaly that has so far not been detected as primary or recurrent change by G-banding analysis of these tumors, was noted in 2 cases as a unique change. Other recurrent changes included gains of 9q, 11q, 12q, 15q, 17q, and 22q and losses of 6q and 16q. We have been able to narrow the commonly deleted regions on 6q and 13q to bands 6q21 and 13q14-21. Gain of 11q and deletion of 13q, which have previously been associated with poor outcome, can thus be detected by CGH, allowing the use of this technique for prognostic evaluation of patients, without relying on the success of conventional cytogenetic analysis.

Entities:  

Mesh:

Year:  1998        PMID: 9531613

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

2.  Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Authors:  N Bolli; G Biancon; M Moarii; S Gimondi; Y Li; C de Philippis; F Maura; V Sathiaseelan; Y-T Tai; L Mudie; S O'Meara; K Raine; J W Teague; A P Butler; C Carniti; M Gerstung; T Bagratuni; E Kastritis; M Dimopoulos; P Corradini; K Anderson; P Moreau; S Minvielle; P J Campbell; E Papaemmanuil; H Avet-Loiseau; N C Munshi
Journal:  Leukemia       Date:  2017-12-06       Impact factor: 11.528

3.  Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.

Authors:  Daniel W Sherbenou; Blake T Aftab; Yang Su; Christopher R Behrens; Arun Wiita; Aaron C Logan; Diego Acosta-Alvear; Byron C Hann; Peter Walter; Marc A Shuman; Xiaobo Wu; John P Atkinson; Jeffrey L Wolf; Thomas G Martin; Bin Liu
Journal:  J Clin Invest       Date:  2016-11-14       Impact factor: 14.808

4.  CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.

Authors:  Hong Chang; Nan Jiang; Hua Jiang; Manujendra N Saha; Connie Qi; Wei Xu; Donna Reece
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

5.  Integrating cytogenetics and gene expression profiling in the molecular analysis of multiple myeloma.

Authors:  John D Shaughnessy; Bart Barlogie
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

6.  Amplification of 1q21 and other abnormalities in multiple myeloma patients from a tertiary hospital in singapore.

Authors:  Alvin S T Lim; Sathish Krishnan; Tse Hui Lim; Karen See; Yit Jun Ng; Yu Min Tan; Natasha Choo; Lai Ching Lau; Sim Leng Tien; Jun Ma; Daryl Tan
Journal:  Indian J Hematol Blood Transfus       Date:  2013-09-04       Impact factor: 0.900

7.  Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer.

Authors:  Esteban Ballestar; Maria F Paz; Laura Valle; Susan Wei; Mario F Fraga; Jesus Espada; Juan Cruz Cigudosa; Tim Hui-Ming Huang; Manel Esteller
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

Review 8.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

Review 9.  Molecular aspects of multiple myeloma.

Authors:  G Pratt
Journal:  Mol Pathol       Date:  2002-10

10.  Prognostic significance of copy-number alterations in multiple myeloma.

Authors:  Hervé Avet-Loiseau; Cheng Li; Florence Magrangeas; Wilfried Gouraud; Catherine Charbonnel; Jean-Luc Harousseau; Michel Attal; Gerald Marit; Claire Mathiot; Thierry Facon; Philippe Moreau; Kenneth C Anderson; Loïc Campion; Nikhil C Munshi; Stéphane Minvielle
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.